# Regeneron: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Regeneron Pharmaceuticals, Inc. · NASDAQ: REGN · Sector: Health Care

Updated for Q3 FY2026 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/regeneron. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Regeneron: how the business works", with the page URL.

## The 30-second summary

Regeneron invents and makes antibody and other protein medicines, with $14.34 billion of revenue in FY2025. It sells EYLEA HD, EYLEA and Libtayo itself in the US, and Sanofi collaboration revenue, mostly its share of Dupixent profits, was 41.0% of FY2025 revenue. US EYLEA sales fell from $4.77 billion in FY2024 to $2.75 billion in FY2025, after EYLEA's US exclusivity ended in May 2024.

## 5 points

- **What it sells:** Regeneron sells antibody and other protein medicines; sales of its own medicines were $6.31 billion of its $14.34 billion FY2025 revenue, and US EYLEA sales were $2.75 billion. [S4]
- **Who pays it:** In FY2025, distributors buying Regeneron's own medicines paid 44% of revenue, Sanofi's profit share (mainly Dupixent) 41%, Bayer 9.9% and royalties and other 5.1%. [S4]
- **What it keeps from $100:** Of every $100 that came in during FY2025, Regeneron kept $28.1 as net income, which includes $10.6 of interest and investment income; operating income was $24.9 per $100 of revenue. [S4]
- **Where the operating profit comes from:** Regeneron reports one business segment and no profit by product; its largest revenue line, the Sanofi collaboration, was $5.88 billion, 41.0% of FY2025 revenue. [S4]
- **The one thing to watch:** US sales of EYLEA HD rose to $698.8 million in Q3 FY2026 from $430.6 million a year earlier, while older EYLEA fell to $399.7 million from $680.6 million. [S1]

## What does Regeneron sell?

Regeneron invents antibody medicines, given as injections, and makes them in its own plants. It sells some itself in the US. Others are sold by partners Sanofi and Bayer, who share the profits with Regeneron.

- **EYLEA HD and EYLEA:** Eye injections for wet age-related macular degeneration and diabetic eye disease. Regeneron sells them in the US; Bayer sells them elsewhere. [S4]
- **Dupixent (with Sanofi):** Injection for atopic dermatitis (eczema) and asthma. Sanofi records the sales, $17.81 billion in FY2025, and Regeneron earns a share of the profits. [S4]
- **Libtayo:** Cancer medicine, including for a type of skin cancer (cutaneous squamous cell carcinoma). Regeneron sold $1.45 billion of it worldwide in FY2025. [S4, S16]
- **Smaller medicines:** Praluent, Evkeeza, Inmazeb and others. Together they were $472.2 million of FY2025 sales (Cityfort calculation from the FY2025 10-K). [S4]

## Who pays Regeneron?

- **Distributors buying its own medicines (44.0% of revenue):** Wholesalers and specialty distributors buy EYLEA HD, EYLEA, Libtayo and the smaller medicines. Net product sales were $6.31 billion in FY2025. [S4]
- **Sanofi (profit share, mainly Dupixent) (41.0% of revenue):** Sanofi pays Regeneron its share of profits on Dupixent and Kevzara, plus payments for supplying the medicine. $5.88 billion in FY2025. [S4]
- **Bayer (EYLEA outside the US) (9.9% of revenue):** Bayer sells EYLEA HD and EYLEA outside the US and shares the profits equally. $1.42 billion in FY2025. [S4]
- **Royalties and other (5.1% of revenue):** Includes royalties on Novartis's Ilaris and Regeneron's share of ARCALYST profits, plus other collaboration revenue. $727.4 million in FY2025. [S4]
- **Customer concentration:** Two unnamed distributors bought 50% and 27% of Regeneron's gross product sales in FY2025, 77% together. Separately, Sanofi collaboration revenue was 41.0% of total revenue. [S4]

## Where the money went (FY2025)

1. Regeneron took in $14.34 billion of revenue in FY2025, and its investments added $1.70 billion of other income.
2. Collaboration revenue, mostly Regeneron's share of Dupixent profits from Sanofi, was $7.33 billion, more than its $6.31 billion of own product sales.
3. Research took $5.85 billion, and selling and admin took $2.70 billion.
4. Making medicines, its own and those it supplies to partners, cost $2.10 billion.
5. After $725.8 million of income tax, $4.50 billion was left as net income.

Sources: S4.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2021 | 16,071.7 | 9,233 | 57.4% | 8,075.3 | 50.2% | 71.97 | 7,081.3 | 551.9 | 6,529.4 | S14 |
| FY2022 | 12,172.9 | 5,080.3 | 41.7% | 4,338.4 | 35.6% | 38.22 | 5,014.9 | 590.1 | 4,424.8 | S13 |
| FY2023 | 13,117.2 | 4,468.1 | 34.1% | 3,953.6 | 30.1% | 34.77 | 4,594 | 718.6 | 3,875.4 | S12 |
| FY2024 | 14,202 | 4,473.6 | 31.5% | 4,412.6 | 31.1% | 38.34 | 4,420.5 | 755.9 | 3,664.6 | S8 |
| FY2025 | 14,342.9 | 4,121.6 | 28.7% | 4,504.9 | 31.4% | 41.48 | 4,978.9 | 898.4 | 4,080.5 | S4 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

Cash and marketable securities of $18.86 billion on Sep 30, 2026 were about 9.5 times Regeneron's $1.99 billion of notes. [S16, S4, S1]

| Item | Value |
| --- | --- |
| Total debt | 1,987 |
| Cash and investments | 18,858.5 |
| Net debt (debt minus cash) | −16,871.5 |
| Net worth (shareholders' money) | 33,498.5 |
| Debt to equity (times) | 0.06 |

- Net cash of $16.87 billion = cash and marketable securities minus long-term debt (Cityfort calculation from the Q3 FY2026 earnings release).
- The debt is two bond issues: 1.750% notes due 2030 and 2.800% notes due 2050. A $720.0 million finance lease is shown separately and not counted as debt here.
- A $750.0 million revolving credit line had nothing drawn on Sep 30, 2026.

## Who owns Regeneron? (as of Apr 14, 2026)

Class A shares carry 10 votes each. Directors and officers held 5.2% of the common stock and 17.6% of the votes on Sep 30, 2026, the 10-Q says. Rows have different dates and are never added. [S15, S1]

- Officers and directors (as a group), shares: 5.2%
- Officers and directors (as a group), votes: 17.6%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (101,630,713 shares on Oct 22, 2026 (10-Q cover). Trades on Nasdaq as REGN.) | 101.63 | 1 | — | — | Yes | S1 |
| Class A stock (1,817,146 shares, 15.2% of all votes on Sep 30, 2026. Converts into common stock one for one.) | 1.82 | 10 | — | 15.2% | No | S1, S15 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The Vanguard Group | 8.6% | — | Feb 13, 2024 | Proxy figure from a Schedule 13G/A filed Feb 13, 2024. The proxy notes Vanguard reported on Mar 27, 2026 that it no longer beneficially owns these shares after an internal realignment. | S15 |
| BlackRock, Inc. | 8.4% | — | Jan 25, 2024 | Proxy figure from a Schedule 13G/A filed Jan 25, 2024 (8,629,707 shares). | S15 |
| Capital World Investors | 5.0% | — | Feb 9, 2024 | Proxy figure from a Schedule 13G/A filed Feb 9, 2024 (5,194,729 shares). | S15 |
| Leonard S. Schleifer (co-founder, CEO) | 2.8% | — | Apr 14, 2026 | Holds 1,725,565 Class A shares, 95.0% of that class; the 2.8% assumes they convert into common stock. | S15 |

## What could go wrong

### Biosimilar copies of EYLEA

EYLEA's US regulatory exclusivity ended in May 2024, and copies such as Amgen's Pavblu have been approved or launched. US EYLEA sales fell from $4.77 billion in FY2024 to $2.75 billion in FY2025. [S1, S4]

What to watch: Combined US sales of EYLEA HD and EYLEA each quarter ($1.10 billion in Q3 FY2026, the Q3 FY2026 10-Q says).

### Reliance on Dupixent and Sanofi

The 10-K says Regeneron depends heavily on Sanofi collaboration revenue, mainly Dupixent profits. It was 41.0% of FY2025 revenue. [S4]

What to watch: Dupixent global sales and Sanofi collaboration revenue in each release.

### Two distributors buy most products

Two unnamed customers bought 50% and 27% of gross product sales in FY2025. They owed 87% of trade receivables at Dec 31, 2025. [S4]

What to watch: Customer shares in the 10-Q product sales note.

### Government and payer lawsuits

US Attorney's complaints filed in June 2020 and March 2024 allege Anti-Kickback and False Claims Act violations. Insurers such as UnitedHealthcare and Humana have filed related suits. [S1]

What to watch: Rulings on the alleged violations, as reported in the legal note of each 10-Q.

### Manufacturing problems

A temporary manufacturing interruption raised costs in the first half of 2026. It took about 3 points off the nine-month 2026 GAAP gross margin on product sales, which was 79%. [S16, S18]

What to watch: Gross margin on product sales against the company's "about 80%" 2026 guidance.

### Research may not pay off

Research spending was $5.85 billion in FY2025, $40.8 of every $100 of revenue (Cityfort calculation from the FY2025 10-K). Trials can fail or be delayed. [S4, S16]

What to watch: The FDA's February 2027 target action date for Ordspono, stated in the Q3 FY2026 release (Oct 30, 2026).

### Founder voting control

Class A shares have 10 votes each. Directors and officers held 17.6% of the votes on Sep 30, 2026, against 5.2% of the common stock. [S1]

What to watch: Class A share count and voting share in each 10-Q.

## What to watch

Next: Q4 FY2026 results, Date not announced yet.

- **EYLEA HD and EYLEA in the US:** Combined US sales were $1.10 billion in Q3 FY2026, the Q3 FY2026 10-Q says. EYLEA HD rose to $698.8 million while older EYLEA fell to $399.7 million.
- **$1.0 billion from Sanofi:** Regeneron said on Oct 30, 2026 that the $1.0 billion upfront payment under its Oct 1, 2026 Sanofi amendment will be recorded as collaboration revenue in Q4 FY2026.
- **FDA decisions:** Leonard Schleifer said on Oct 30, 2026 that Regeneron expected an FDA decision on cemdisiran in generalized myasthenia gravis in November 2026. The FDA's target date for Ordspono in a type of lymphoma is February 2027.

## Sources

- S1: Form 10-Q for Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm (published Oct 30, 2026)
- S2: Form 10-Q for Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/0000872589-26-000025-index.htm (published Jul 30, 2026)
- S3: Form 10-Q for Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/0000872589-26-000016-index.htm (published Apr 29, 2026)
- S4: Form 10-K for FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm (published Feb 4, 2026)
- S5: Form 10-Q for Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm (published Oct 28, 2025)
- S6: Form 10-Q for Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm (published Aug 1, 2025)
- S7: Form 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm (published Apr 29, 2025)
- S8: Form 10-K for FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm (published Feb 5, 2025)
- S9: Form 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000180422024000040/0001804220-24-000040-index.htm (published Oct 31, 2024)
- S10: Form 10-Q for Q2 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm (published Aug 1, 2024)
- S11: Form 10-Q for Q1 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000180422024000017/0001804220-24-000017-index.htm (published May 2, 2024)
- S12: Form 10-K for FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/0001804220-24-000009-index.htm (published Feb 5, 2024)
- S13: Form 10-K for FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000180422023000008/0001804220-23-000008-index.htm (published Feb 6, 2023)
- S14: Form 10-K for FY2021. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000180422022000007/0001804220-22-000007-index.htm (published Feb 7, 2022)
- S15: 2026 Proxy Statement (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm (published Apr 24, 2026)
- S16: Q3 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/exhibit991q32026.htm (published Oct 30, 2026)
- S17: Q2 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm (published Jul 30, 2026)
- S18: Q1 FY2026 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm (published Apr 29, 2026)
- S19: Q4 FY2025 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm (published Jan 30, 2026)
- S20: Q4 FY2024 earnings release (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm (published Feb 4, 2025)
- S21: 8-K filed Oct 6, 2026 (Sanofi agreement dated Oct 1, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/tm2627077d1_8k.htm (published Oct 6, 2026)
